Andy Polhamus

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing.

Treatments with JAK inhibitors are continuing to make their way into the MPN space, providing symptom relief, but not yet a cure.

Treatment for patients with non-small cell lung cancer has evolved to include immunotherapy after surgery and chemotherapy.

Biliary duct cancer, or cholangiocarcinoma, has always been known as a difficult-to-treat disease, but immunotherapies may make an impact on patients' lives.

After Marshall Morris was diagnosed with a rare cancer and given only six months to live, he created a charity that empowers people with terminal illness and provides them with counseling and support.

The designation of HER2-low status is rapidly reshaping how researchers and care providers not only think about, but also treat, breast cancer.

A patient with metastatic breast cancer shares how she learned that her disease was recently reclassified as HER-2 low, and what it was like to first learn about the FDA-approved drug years before she would be prescribed the treatment.

Although tumor lysis syndrome may be dangerous and fatal if not treated early, experts note that it is a sign of successful treatment in patients with leukemia and lymphoma.

Three therapeutic breakthroughs are revolutionizing care for triple-negative breast cancer and saving women’s lives.

Remission should lift the burden of cancer, but the effects that follow treatment may keep many cancer survivors from being able to sleep at night.

Patients with this rare genetic condition develop tumors in various parts of their body, throughout their lifetime, requiring a multidisciplinary care team and constant screening and management.